Osaic Holdings Inc. Boosts Holdings in Lantheus Holdings, Inc. $LNTH

Osaic Holdings Inc. raised its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 218.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,177 shares of the medical equipment provider’s stock after buying an additional 15,900 shares during the period. Osaic Holdings Inc.’s holdings in Lantheus were worth $2,026,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Elevation Point Wealth Partners LLC bought a new stake in shares of Lantheus during the 2nd quarter valued at $26,000. Osterweis Capital Management Inc. purchased a new position in Lantheus during the second quarter valued at $36,000. Quarry LP grew its holdings in Lantheus by 2,350.0% during the first quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 470 shares during the period. EverSource Wealth Advisors LLC increased its position in Lantheus by 190.2% in the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after buying an additional 698 shares in the last quarter. Finally, EMC Capital Management bought a new position in shares of Lantheus in the second quarter worth about $93,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. B. Riley cut their price objective on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, September 16th. Mizuho lifted their price target on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Truist Financial increased their price objective on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. The Goldman Sachs Group set a $77.00 price objective on shares of Lantheus and gave the company a “neutral” rating in a research report on Wednesday, October 8th. Finally, Weiss Ratings downgraded shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $78.00.

Lantheus Price Performance

LNTH stock opened at $66.71 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. The company’s fifty day moving average price is $58.96 and its 200-day moving average price is $62.10. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $111.29. The company has a market capitalization of $4.42 billion, a PE ratio of 28.03 and a beta of -0.10.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The company had revenue of $92.51 million for the quarter. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.